Drugs / ADXS-503
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03847519 | Feb 2019 → Feb 2022 | non-small cell lung carcinoma, squamous cell carcinoma | Advaxis, Inc. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ADXS-503 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03847519 ↗ |
| Modality | Other / unclassified | “A live attenuated Listeria monocytogenes (Lm)-based immunotherapy bioengineered to elicit T cell responses against shared tumor antigens commonly found in patients with...” NCT03847519 ↗ |
| Route | Intravenous | “1e8 CFU of ADXS-503, IV, every 3 weeks until disease progression, unacceptable toxicity, or another treatment discontinuation criterion is met.” NCT03847519 ↗ |